Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours: Chengdu, China Friday, March 28, 2025, 15:00 H ...
Endometriosis is a chronic inflammatory condition caused due to abnormal appearance of the uterine lining. Dr Shilpa Singhal: Our Bureau, Chennai Friday, March 28, 2025, 14:30 Hrs ...
South San Francisco, California Friday, March 28, 2025, 14:00 Hrs [IST] ...
NCLT approves Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals: Our Bureau, Bengaluru Friday, March 28, 2025, 14:15 Hrs [IST] Suven Pharmaceuticals a ...
USC-licensed startup NeOnc Technologies gets Nasdaq listing, unveils India clinical trial expansion: Our Bureau, Bengaluru Friday, March 28, 2025, 13:30 Hrs [IST] A USC-licensed s ...
BluHeat by Nysh.in launches innovative Cough Decongestion Patches with air activated technology: Our Bureau, Bengaluru Friday, March 28, 2025, 13:45 Hrs [IST] Nysh.in, a pioneerin ...
Bayer, Puhe BioPharma ink global license agreement for clinical phase I PRMT5 inhibitor: Berlin, Germany Friday, March 28, 2025, 13:00 Hrs [IST] Bayer and Suzhou Puhe BioPharma Co ...
US FDA grants fast track designation to Sanofi’s mRNA vaccine candidate for prevention of chlamydia infection: Paris Friday, March 28, 2025, 12:00 Hrs [IST] The US Food and Drug ...
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...
Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...
Peethaambaran Kunnathoor, Chennai Friday, March 28, 2025, 08:00 Hrs [IST] ...
A total of 446 Memorandums of Understanding (MoUs) have been signed in the healthcare and pharmaceutical sectors, bringing an impressive proposed investment of Rs. 49,471.15 crore as part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results